SELLAS Life Sciences
20 hedge funds and large institutions have $5.1M invested in SELLAS Life Sciences in 2018 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 6 increasing their positions, 1 reducing their positions, and 5 closing their positions.
4,050% more call options, than puts
Call options by funds: $166K | Put options by funds: $4K
500% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 1
100% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 5
62% more capital invested
Capital invested by funds: $3.16M → $5.1M (+$1.95M)
33% more funds holding
Funds holding: 15 → 20 (+5)
0.11% more ownership
Funds ownership: 0.26% → 0.38% (+0.11%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$968K |
| 2 |
Renaissance Technologies
New York
|
+$689K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$401K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$177K |
| 5 |
BlackRock
New York
|
+$162K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$96K |
| 2 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$21K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$16.8K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$16K |
| 5 |
MAM
Meeder Asset Management
Dublin,
Ohio
|
-$6.5K |
SLS Hedge Fund Activity: Q4 2018 in Review
20 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in SELLAS Life Sciences (SLS) for Q4 2018, worth a combined $5.1M — up 62% from $3.16M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new SLS positions and 5 closed out — a net gain of 5 holders — while 6 added to existing stakes and 1 trimmed.
The largest buyer was 683 Capital Management, adding an estimated $968K. The largest seller was Sabby Management, exiting entirely with an estimated $96K sold.
- 20 institutional investors held SELLAS Life Sciences (SLS) as of Q4 2018, up from 15 in Q3 2018.
- Funds reported $5.1M of SELLAS Life Sciences stock for Q4 2018, up 62% quarter-over-quarter.
- 10 funds opened new SELLAS Life Sciences positions in Q4 2018 and 5 closed out, a net change of +5 holders.
- The largest SELLAS Life Sciences buyer in Q4 2018 was 683 Capital Management, an estimated $968K added.
- The largest SELLAS Life Sciences seller in Q4 2018 was Sabby Management, an estimated $96K sold.
Based on aggregated 13F filings for Q4 2018.